Lyell Immunopharma Q3 net loss widens 17% to $45.53 million
LYEL•Lyell Immunopharma’s third-quarter 2026 net loss widened 17% year over year to $45.53 million. Research and development expenses rose 45% to $40.9 million, while an $80 million private placement is expected to extend its cash runway into 2028.
1. Quarterly results and outlook
Lyell Immunopharma’s third-quarter 2026 net loss widened 17% year over year to $45.53 million, while research and development expenses increased 45% to $40.9 million, primarily due to increased clinical trial activity. The company expects an $80 million private placement to extend its cash runway into 2028. Ronde-cel pivotal data are expected in mid-2027, with a Biologics License Application submission planned for the second half of 2027.
